SanegeneBio & Eli Lilly Sign Global Partnership to Advance RNAi Therapies for Metabolic Diseases

SanegeneBio, a biotechnology company specializing in RNAi therapeutics, today announced a global research collaboration and licensing agreement with Eli Lilly (NYSE: LLY). The two parties will jointly leverage SanegeneBio’s proprietary LEAD platform to accelerate the discovery and development of RNAi candidates that target metabolic disorders.

Partnership Highlights

• Technology – SanegeneBio will employ the LEAD platform to screen and identify the most potent RNAi active molecules for the collaboration.
• Drug Development Pathway – Eli Lilly will lead all Investigational New Drug (IND) enabling studies, clinical development, and eventual commercialization of the compounds.
• Financial Terms – SanegeneBio receives an upfront payment and an equity injection, with the potential for up to USD 1.2 billion in milestone payments and tiered royalties on commercial sales.

Strategic Rationale

• For SanegeneBio – Access to Eli Lilly’s global R&D, regulatory, and commercial platforms, thereby accelerating the path from bench to bedside.
• For Eli Lilly – Integration of a cutting‑edge RNAi discovery platform within its expanding metabolic disease program, broadening its therapeutic portfolio.
• Industry Impact – The alliance underscores the growing momentum of RNAi as a viable modality for complex metabolic conditions such as type 2 diabetes, non‑alcoholic fatty liver disease, and dyslipidemia.

Timeline & Next Steps

Forward‑Looking Statements
This release contains forward‑looking statements regarding future milestones, regulatory approvals, and commercial prospects. Actual results may differ materially from those expressed herein.-Fineline Info & Tech